From therapeutic drug monitoring to total drug monitoring and drug-omics

AbstractIn view of the role of pharmacotherapy in medicine, on the one hand, and the powerful technical possibilities that are now available on the other hand, therapeutic drug monitoring is a surprisingly neglected area of laboratory medicine. In this viewpoint article, an “omics approach” to pharmacovigilance and drug monitoring is proposed and discussed. A realistic goal for laboratory medicine in the 21st century should indeed be to enable clinicians to check whether the right drug is present in the right patient with an appropriate blood concentration for each compound.

Download Full-text

Central Nervous System Toxicity of Tricyclic Antidepressants: Phenomenology, Course, Risk Factors, and Role of Therapeutic Drug Monitoring

Journal of Clinical Psychopharmacology ◽

10.1097/00004714-199004000-00003 ◽

1990 ◽

Vol 10 (2) ◽

pp. 88-95 ◽

Cited By ~ 77

Author(s):

SHELDON H. PRESKORN ◽

GEORGE S. JERKOVICH

Keyword(s):

Risk Factors ◽

Central Nervous System ◽

Nervous System ◽

Therapeutic Drug Monitoring ◽

Drug Monitoring ◽

Tricyclic Antidepressants ◽

Therapeutic Drug ◽

Central Nervous System Toxicity ◽

System Toxicity

Download Full-text

The role of therapeutic drug monitoring in treatment of HIV infection

British Journal of Clinical Pharmacology ◽

10.1111/j.1365-2125.2001.00380.x ◽

2001 ◽

Vol 52 (S1) ◽

pp. 89-96

Author(s):

David J. Back ◽

Saye H. Khoo ◽

Sara E. Gibbons ◽

Concepta Merry

Keyword(s):

Therapeutic Drug Monitoring ◽

Hiv Infection ◽

Drug Monitoring ◽

Therapeutic Drug

Download Full-text

Role of Therapeutic Drug Monitoring and Challenges in the Management of Infantile Chronic Myeloid Leukemia

Pediatric Oncall ◽

10.7199/ped.oncall.2021.16 ◽

2021 ◽

Vol 18 (2) ◽

Author(s):

Sneha Tandon ◽

Raviraj Deshpande ◽

Gaurav Narula ◽

Maya Prasad ◽

Amey Paradkar ◽

...

Keyword(s):

Chronic Myeloid Leukemia ◽

Therapeutic Drug Monitoring ◽

Drug Monitoring ◽

Myeloid Leukemia ◽

Therapeutic Drug

Download Full-text

Can We Rely on AGNP Therapeutic Targets Also For LAI Antipsychotics?

Pharmacopsychiatry ◽

10.1055/s-0043-122603 ◽

2017 ◽

Vol 51 (06) ◽

pp. 270-271 ◽

Cited By ~ 1

Author(s):

Sara Baldelli ◽

Emilio Clementi ◽

Dario Cattaneo

Keyword(s):

Clinical Practice ◽

Therapeutic Drug Monitoring ◽

Drug Monitoring ◽

Atypical Antipsychotics ◽

Therapeutic Targets ◽

Therapeutic Drug ◽

Consensus Guidelines ◽

Long Acting

AbstractThe updated AGNP Consensus Guidelines for Therapeutic Drug Monitoring (TDM) in Neuropsychopharmacology recently published in the journal have reinforced the key role of TDM to individualize psychoparmacological therapies in clinical practice. However, we believe, that these guidelines have missed the important opportunity to face with, and to provide useful information on, the emerging issue of long-acting injectable formulations of atypical antipsychotics. Specific therapeutic ranges also for these formulations should be included in the next AGNP guidelines.

Download Full-text

Part I General Aspects, 2 The IPO Process, IPO Disclosure, and the Prospectus Regulation

Prospectus Regulation and Prospectus Liability ◽

10.1093/law/9780198846529.003.0002 ◽

2020 ◽

Author(s):

Teerink Han

Keyword(s):

Initial Public Offering ◽

The Other ◽

Business Information ◽

Other Hand ◽

The One ◽

General Aspects ◽

Public Offering ◽

The Right ◽

Insight Into

This chapter offers insight into a typical initial public offering (IPO) process, highlighting key practical and legal considerations around disclosure, through the IPO prospectus and otherwise. The prospectus plays a key role in the preparations for, and execution of, an IPO. As an IPO prospectus typically constitutes a company's first public dissemination of financial and business information, the company and other parties involved in the IPO process must carefully consider the right balance between, on the one hand, drafting the IPO prospectus as a marketing document introducing the company and its business to potential investors, whilst, on the other hand, being able to use the prospectus as a disclosure document that protects the company against liability arising from claims from investors or others after the IPO. Here, the chapter summarizes the different phases in an IPO process and the most important documents and parties involved, focusing on the central role of the IPO prospectus. In addition, a number of changes resulting from the enactment of the Prospectus Regulation are likely to be of particular relevance to IPO processes. The expected impact of these changes is therefore also discussed.

Download Full-text

Pharmacokinetic interpretation of data gathered during therapeutic drug monitoring.

Clinical Chemistry ◽

10.1093/clinchem/22.6.868 ◽

1976 ◽

Vol 22 (6) ◽

pp. 868-878 ◽

Cited By ~ 52

Author(s):

B H Dvorchik ◽

E S Vesell

Keyword(s):

Therapeutic Drug Monitoring ◽

Drug Monitoring ◽

Active Form ◽

Drug Distribution ◽

Drug Clearance ◽

Drug Binding ◽

Therapeutic Drug ◽

The One ◽

Pharmacologically Active ◽

Organ Clearance

Abstract We review some pharmacokinetic principles that can facilitate interpretation of data obtained during therapeutic drug monitoring: the one- and two-compartment models, volume of drug distribution, drug clearance, organ clearance, bioavailability, first-pass effect, chronic or repetitive dosing, and use of urine and saliva to measure drug clearance and drug binding to plasma proteins, respectively. We also describe use of saliva to estimate rapidly, conveniently, and noninvasively the concentration of the free, pharmacologically active form of the drug as well as the fraction of drug bound to plasma protein.

Download Full-text

Neural and Kernal Methods for Therapeutic Drug Monitoring

Neural Networks in Healthcare ◽

10.4018/978-1-59140-848-2.ch011 ◽

2011 ◽

pp. 238-261 ◽

Cited By ~ 1

Author(s):

G. Camps-Valls ◽

J. D. Martin-Guerrero

Keyword(s):

Therapeutic Drug Monitoring ◽

Drug Monitoring ◽

Substantial Improvement ◽

Physical Models ◽

Therapeutic Drug ◽

Optimal Dosage ◽

Blood Concentrations ◽

Clinical Problems

Recently, important advances in dosage formulations, therapeutic drug monitoring (TDM), and the emerging role of combined therapies have resulted in a substantial improvement in patients’ quality of life. Nevertheless, the increasing amounts of collected data and the non-linear nature of the underlying pharmacokinetic processes justify the development of mathematical models capable of predicting concentrations of a given administered drug and then adjusting the optimal dosage. Physical models of drug absorption and distribution and Bayesian forecasting have been used to predict blood concentrations, but their performance is not optimal and has given rise to the appearance of neural and kernel methods that could improve it. In this chapter, we present a complete review of neural and kernel models for TDM. All presented methods are theoretically motivated, and illustrative examples in real clinical problems are included.

Download Full-text